小儿支原体肺炎抗菌治疗的研究进展

Advances in the Treatment of Antibiotic of Mycoplasma Pneumonia in Children

肺炎支原体是小儿社区获得性呼吸道感染的主要病原体之一,小儿肺炎支原体感染约占小儿急性呼吸道感染的20%左右,且其发病率逐年升高。除引起呼吸系统病变外,还可导致患儿机体多系统器官功能障碍,甚至引起患儿死亡,临床治疗药物以抗生素、免疫制剂及中医为主,本文对小儿支原体肺炎抗菌治疗的进展作一综述。

Mycoplasma pneumonia in children was one of the main pathogens of community acquired respiratory tract infection, mycoplasma pneumoniae infection in children with acute respiratory tract infection accounted for about 20%, and its incidence was increasing year by year. In addition to cause respiratory system disease, it can also lead to children with the multiple system organ dysfunction, and even cause death. Clinical treatment was with antibiotics, drugs, immune preparation and traditional Chinese medicine, this paper made a review on the progress in treatment of children with mycoplasma pneumonia antibiotic.